A potential new drug might protect infants from whooping cough in their first few months of life before they can be vaccinated, early research suggests.
In a new study, researchers gave this drug to baboons just after they were born, and found that the drug protected the animals when they were subsequently infected with the bacteria that cause whooping cough.
The study was presented here Thursday (Oct. 5) at an infectious disease conference called IDWeek 2017.
Human infants are most vulnerable to whooping cough during their first two months of life — when they are too young to get the whooping cough vaccine. (Babies' immune systems are not mature enough to respond to the whooping cough vaccine until they are 2 months old.) For this reason, women are advised to get the whooping cough vaccine, called Tdap, during pregnancy, so that they can pass protective antibodies to the fetus before birth, according to the Centers for Disease Control and Prevention (CDC).
But not all pregnant mothers get the whooping cough vaccine — among U.S. women who gave birth between fall 2015 and spring 2016, less than half (49 percent) received the recommended vaccine, according to the CDC.
"It's hard to get 100 percent of all mothers vaccinated," said Jennifer Maynard, an associate professor in the Department of Chemical Engineering at The University of Texas at Austin, and lead author of the new study.
A potential solution to this problem would be to give infants a drug as soon as they are born that would protect them against whooping cough.
Maynard and her colleagues investigated such a drug in their study. The drug contains an antibody — an immune system protein that binds to harmful pathogens to stop infection. In this case, the antibody, called hu1B7, binds to the toxin produced by whooping cough bacteria and renders the toxin harmless.
"It's essentially giving you instant immunity as if the baby has been fully vaccinated," Maynard told Live Science.
In the new study, the researchers gave hu1B7 to seven baboons a few days after they were born, and compared them with another seven baboons who did not receive hu1B7. When the animals were later infected with whooping cough bacteria, called Bordetella pertussis, all of the baboons that received hu1B7 appeared normal and didn't develop any symptoms of whooping cough. In contrast, the baboons that did not receive hu1B7 got sick, and four had to be euthanized, Maynard said.
The study was funded in part by Synthetic Biologics, a biotechnology company that is developing the drug with hu1B7. The study was also funded by The Bill & Melinda Gates Foundation and the U.S. National Institutes of Health.
Unlike a vaccine, hu1B7 antibodies don't provide long-term protection — the antibodies are degraded and cleared from the body after a limited amount of time, Maynard said. The hu1B7 drug has a "half-life" of about 25 days in people, meaning that about half of the drug is cleared from the body in that time. But Maynard and colleagues have engineered a slightly different version of hu1B7 that doesn't degrade as quickly. Based on their animal studies, the researchers hypothesize that this altered version of hu1B7 would have a half-life in people of 80 to 100 days.
If this turns out to be true, "then you could give one dose and it could really protect [infants] for that whole period during which babies are most susceptible," Maynard said.
The next step is to conduct a trial in humans to see if the findings from the animal studies hold true in people. Synthetic Biologics has an "orphan drug" designation for its drug, which allows the company to move forward more quickly with a human trial, Maynard said.
An earlier study by Synthetic Biologics also found that hu1B7, combined with a second antibody called hu11E6, was effective at treating Bordetella pertussis infection in baboons. The company is considering the possibility of testing the drug for prevention or treatment of whooping cough.
You need to be logged in to save this episode to a playlist.
You must be logged in to display playlists.